Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Payables (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Payables for 6 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables rose 23.47% to $5.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.0 million, a 23.47% increase, with the full-year FY2025 number at $5.0 million, up 23.47% from a year prior.
  • Payables was $5.0 million for Q4 2025 at Janux Therapeutics, up from $3.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $5.0 million in Q4 2025 to a low of $354000.0 in Q2 2021.
  • A 5-year average of $2.6 million and a median of $2.5 million in 2021 define the central range for Payables.
  • Peak YoY movement for Payables: soared 747.46% in 2022, then crashed 36.33% in 2023.
  • Janux Therapeutics' Payables stood at $2.5 million in 2021, then decreased by 12.16% to $2.2 million in 2022, then rose by 12.27% to $2.4 million in 2023, then soared by 66.09% to $4.0 million in 2024, then rose by 23.47% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Payables are $5.0 million (Q4 2025), $3.4 million (Q3 2025), and $3.5 million (Q2 2025).